Clinical trialPhase 2Active not recruiting
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 3 March 2017
- Expected end
- 30 September 2027
- Enrollment
- 133 participants
- Sites
- 1
- Primary outcomes
- Objective response
- Sponsor
- Other
- Results posted
- No
- Last update
- 14 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Detailed description public domain (ClinicalTrials.gov)
PRIMARY OBJECTIVES: I. To evaluate the efficacy of atezolizumab when given in combination with bevacizumab (atezo bev). SECONDARY OBJECTIVES: I. To evaluate the efficacy of atezo bev. II. To evaluate the safety of atezo + bev. EXPLORATORY BIOMARKER OBJECTIVES: I. To identify biomarkers that are predictive of response to atezo bev (i.e., predictive biomarkers), are associated with progression to a more severe disease state (i.e., prognostic biomarkers), are associated with resistance to atezo bev, are associated with susceptibility to developing adverse events, can provide evidence of study treatment activity, or can increase the knowledge and understanding of disease biology. OUTLINE: Patients receive atezolizumab and bevacizumab intravenously (IV) over 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months.